文献速递组学、生物样本库与精准医学流行病学与生物统计基础与转化研究

APOL1高危基因型个体的蛋白质组风险评分早期预测肾病进展

Proteomic risk score for early prediction of kidney disease progression in individuals with APOL1 high-risk genotypes.
PubMed 文献 · Nat Med · 2026-04-15

研究在851名APOL1高危基因型且eGFR≥60的非洲裔参与者中,通过弹性网络Cox回归构建九蛋白APOL1蛋白质组风险评分(APRS),预测eGFR下降≥40%、肾衰竭或死亡的复合结局,tAUC达86.5%,外部验证tAUC 82-85%。

要点

  • APRS在APOL1高危人群中10年事件率最高与最低五分位分别为62.5%与3.3%。
  • APRS的tAUC为86.5%,优于肾衰竭风险方程(66.1%)和多基因风险评分。
  • APRS组分蛋白与肾组织纤维化及肾小管损伤通路相关,支持生物学合理性。

核心结论

  • APRS可早期准确预测APOL1高危基因型个体的肾病进展,桥接遗传易感性与临床转化。

研究设计与样本

  • 研究纳入851名非洲裔APOL1高危基因型且eGFR≥60 ml min-1 1.73 m-2的Penn Medicine BioBank参与者,其中男性285名、女性566名。
  • 采用弹性网络Cox回归(校正年龄、性别、eGFR和蛋白尿)推导九蛋白APRS,预测复合结局。
  • 在Atherosclerosis Risk in Communities和UK Biobank队列中进行外部验证。

主要发现

  • APRS预测复合结局(eGFR下降≥40%、肾衰竭或死亡)的tAUC为86.5%。
  • APRS的10年事件率在风险五分位间分别为62.5%与3.3%。
  • 外部验证tAUC为82-85%,在不同人口学和临床亚组中表现一致。
  • APRS组分蛋白血浆水平与肾组织纤维化和肾小管损伤通路相关。

关键数值与推荐

  • APRS的tAUC为86.5%,优于肾衰竭风险方程的66.1%和多基因风险评分。
  • 外部验证tAUC为82-85%。
  • 10年事件率在风险五分位间为62.5% versus 3.3%。

临床怎么用

  • APRS可用于APOL1高危基因型且eGFR≥60个体的早期肾病进展风险分层。
  • 该评分 scalable 且具生物学信息,为早期干预和APOL1靶向治疗开发提供精准医学框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Individuals of African ancestry carrying APOL1 (apolipoprotein L1) high-risk genotypes face a markedly increased risk of kidney failure, yet tools to identify those individuals likely to progress to chronic kidney disease are lacking. Here we profiled plasma proteomes of 851 Penn Medicine BioBank participants of African ancestry (285 males and 566 females) with APOL1 high-risk genotypes and preserved estimated glomerular filtration rate (eGFR) (≥60 ml min-1 1.73 m-2). Using elastic net Cox regression adjusted for age, sex, eGFR and albuminuria, we derived a nine-protein APOL1 Proteomic Risk Score (APRS) that predicts a composite outcome of ≥40% eGFR decline, kidney failure or death. APRS achieved a time-dependent area under the receiver operating characteristic curve (tAUC) of 86.5%, outperforming the Kidney Failure Risk Equation (66.1%) and polygenic risk scores, with 10-year event rates of 62.5% versus 3.3% across risk quintiles. External validation in Atherosclerosis Risk in Communities and UK Biobank cohorts confirmed robust accuracy (tAUC 82-85%) and consistent performance across demographic and clinical subgroups. Plasma levels of APRS component proteins correlated with kidney tissue fibrosis and tubular injury pathways, indicating strong biological plausibility. By enabling early and accurate prediction of disease progression in APOL1 high-risk individuals, APRS bridges the gap between genetic susceptibility and clinical translation. This scalable and biologically informed approach provides a precision medicine framework for early intervention and may accelerate development of APOL1-targeted therapies to reduce kidney disease disparities.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Li C, Richards SM, Quinn G, et al. Proteomic risk score for early prediction of kidney disease progression in individuals with APOL1 high-risk genotypes. Nat Med. 2026. PMID: 41986737. doi:10.1038/s41591-026-04337-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。